STAT Plus: More than 100 small biotech CEOs sound off against Pelosi’s signature drug pricing bill
WASHINGTON — Nearly 150 CEOs of emerging biotech companies are sending a unified, stark message to Capitol Hill: Abandon the Democrats’ signature drug pricing policy.
In a new letter, signed by buzzy biotech startups like Global Blood Therapeutics and Alnylam Pharmaceuticals, the executives lob a blistering critique of the signature drug pricing bill unveiled this fall by House Speaker Nancy Pelosi. The legislation would allow Medicare to negotiate the price of certain high cost drugs and wage huge fines for companies that don’t comply.
Continue to STAT Plus to read the full story…
